Luye Pharma Group, Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Luye Pharma Group, Ltd.
CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.
Having already launched one of its denosumab biosimilar products in China, Boan Biotech has now commenced an international Phase III study to secure approval in Europe, the US and Japan.
Boan Biotech is continuing its ascent in Chinese biosimilars by filing another product with the country’s regulator.
Luye Pharma has claimed a world first after its Boan Biotech subsidiary obtained an approval from China’s NMPA for its Boyoubei denosumab biosimilar rival to Amgen’s Prolia.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Beijing WBL Peking University Biotech Co., Ltd
- Nanjing Luye Sike Pharma Co., Ltd
- Shandong Luye Pharmaceutical Co., Ltd
- Sichuan Luye Baoguang Pharmaceutical Industry Co., Ltd
- Shandong Boan Biological Technology Co. Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.